Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50646 | 0.79 | MAPT (0.68) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL241894 | 0.78 | TSHR (0.60) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL97267 | 0.78 | MAPT (0.50) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL737226 | 0.76 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL27722721 | 0.76 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL163209 | 0.76 | ALDH1A1 (0.72) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL10411946 | 0.76 | ACACB (0.49) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL28677170 | 0.76 | CA1 (0.57) | MAPTHPGDRAB9AL3MBTL1KMT2A | |
| SCHEMBL17313782 | 0.76 | HDAC8 (0.57) | HPGDSMN1; SMN2ACACB | |
| SCHEMBL10001336 | 0.74 | ACACB (0.47) | MAPTHPGDLMNARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106748667-B | Derivative of natural product selaginpulvin, preparation method and application thereof | 中山大学 | 2020-05-08 | — | — | CN | claimed |
| CN-101248056-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | claimed |
| CN-101248066-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | claimed |
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | claimed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| CN-106748667-B | Derivative of natural product selaginpulvin, preparation method and application thereof | 中山大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-1847545-B1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | UBE INDUSTRIES (JP) | 2013-03-06 | — | — | EP | disclosed |
| CN-101248056-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1038880-B1 | Androstanes and pregnanes for allosteric modulation of GABA receptor | EURO CELTIQUE SA (LU) | 2007-10-17 | — | — | EP | disclosed |
| US-6780853-B1 | FOR MODULATING BRAIN EXCITABILITY | EURO-CELTIQUE S.A. (LU) | 2004-08-24 | — | — | US | disclosed |
| EP-1288220-A2 | Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series | Purdue Pharma Ltd. (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-1998005337-A1 | USE OF GABA AND NMDA RECEPTOR LIGANDS FOR THE TREATMENT OF MIGRAINE HEADACHE | COCENSYS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0752860-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996040043-A2 | NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES | COCENSYS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0701444-A1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | COCENSYS, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995021617-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1994027608-A9 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | — | 1995-01-12 | — | — | WO | disclosed |
| WO-1994027608-A1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | COCENSYS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, CYP19A1 | MAPT 4874/4885HPGD 84/4885LMNA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.